Array ( [1614562714] => Array ( [wordfence_processAttackData] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => [args] => Array ( ) ) ) ) [1614562773] => Array ( [wp_privacy_delete_old_export_files] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => hourly [args] => Array ( ) [interval] => 3600 ) ) ) [1614563281] => Array ( [wpm_update_stats] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => hourly [args] => Array ( ) [interval] => 3600 ) ) ) [1614564792] => Array ( [wordfence_hourly_cron] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => hourly [args] => Array ( ) [interval] => 3600 ) ) ) [1614565753] => Array ( [wp_version_check] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => twicedaily [args] => Array ( ) [interval] => 43200 ) ) ) [1614568673] => Array ( [wp_session_garbage_collection] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => twicedaily [args] => Array ( ) [interval] => 43200 ) ) ) [1614579885] => Array ( [recovery_mode_clean_expired_keys] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1614582512] => Array ( [ai1wm_storage_cleanup] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1614588571] => Array ( [wp_scheduled_auto_draft_delete] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1614593711] => Array ( [delete_expired_transients] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1614593752] => Array ( [wpseo-reindex-links] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1614594414] => Array ( [wordfence_daily_cron] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1614605526] => Array ( [wp_update_themes] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => twicedaily [args] => Array ( ) [interval] => 43200 ) ) [wp_update_plugins] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => twicedaily [args] => Array ( ) [interval] => 43200 ) ) ) [1614606274] => Array ( [wp_scheduled_delete] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1614606600] => Array ( [wordfence_start_scheduled_scan] => Array ( [13160efbba8593814ecd3f2a1c16294b] => Array ( [schedule] => [args] => Array ( [0] => 1614606600 ) ) ) ) [1614614824] => Array ( [akismet_scheduled_delete] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1614617811] => Array ( [yoast_tracking] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1614634861] => Array ( [wpseo_permalink_structure_check] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) [wpseo_home_url_check] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1614634874] => Array ( [wpseo-reindex] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1614752690] => Array ( [wp_site_health_scheduled_check] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => weekly [args] => Array ( ) [interval] => 604800 ) ) ) [1614865800] => Array ( [wordfence_start_scheduled_scan] => Array ( [dffdab56ab90aaa0333fa0dd68f73242] => Array ( [schedule] => [args] => Array ( [0] => 1614865800 ) ) ) ) )
Etiquetas: 2006, Acuerdo de precio en Enero-Diciembre 2006, Alglucosidasa Alfa, Condición de dispensación, Dexrazoxano, Dirección general de farmacia y productos sanitarios, Erlotinib, Euros, Galsulfasa, Grupo Terapéutico, Hormona Paratiroidea, Indicaciones, Información, Información contrastada, Madrid, medicamentos, Nombre comercial, Nuevos principios activos autorizados en 2006, Omalizumab, P.V.P, Palonosetron, Pegaptanib, Posaconazol, Presentación, Principio activo, Rotigotina, salud, Sanidad, Sildenafilo, Sorafenib, sunitinib, Tipranavir, Unidad de Utilidad Terapéutica de la Subdirección General de Calidad de Medicamentos.
Etiquetas: 23/03/2008, 32 marzo 2008, Antineoplásticos y agentes inmunomoduladores, Aparato cardiovascular, Aparato genitourinario, Betaína, Galsulfasa, Madrid, Medicamentos huérfanos, Nuevos medicamentos en 2007, Órganos de los sentidos, Órganos hematopoyéticos, Panorama Actual Med 2008, principios activos, Revisión, Revista, salud, Sangre, Sanidad, Sistema nevioso, Terapia antiinfecciosa sistémica, Terapia Hormonal, Tracto alimentario y metabolismo, Varios.